Nanocarriers in tuberculosis treatment: challenges and delivery strategies

M Kumar, T Virmani, G Kumar, R Deshmukh… - Pharmaceuticals, 2023 - mdpi.com
The World Health Organization identifies tuberculosis (TB), caused by Mycobacterium
tuberculosis, as a leading infectious killer. Although conventional treatments for TB exist …

Plant-derived natural products as lead agents against Common Respiratory Diseases

AO Oriola, AO Oyedeji - Molecules, 2022 - mdpi.com
Never has the world been more challenged by respiratory diseases (RDs) than it has
witnessed in the last few decades. This is evident in the plethora of acute and chronic …

[HTML][HTML] The never-ending story of the fight against tuberculosis: from Koch's bacillus to global control programs

M Martini, G Besozzi, I Barberis - Journal of preventive medicine …, 2018 - ncbi.nlm.nih.gov
Tuberculosis (TB) is one of the oldest diseases known to affect humanity, and is still a major
public health problem. It is caused by the bacillus Mycobacterium tuberculosis (MT), isolated …

Inhibition of Mycobacterium tuberculosis InhA (Enoyl-acyl carrier protein reductase) by synthetic Chalcones: a molecular modelling analysis and in-vitro evidence

LS Dhivya, S Sarvesh - Journal of Biomolecular Structure and …, 2023 - Taylor & Francis
Tuberculosis (TB) is a serious infectious disease caused by the bacillus Mycobacterium
tuberculosis (Mtb). The World Health Organization (WHO) estimates that 1.8 million people …

Synthesis, Mycobacterium tuberculosis H37Rv inhibitory activity, and molecular docking study of pyrazinamide analogs

M Zulqurnain, NP Aijijiyah, FA Wati… - Journal of Applied …, 2023 - japsonline.com
Pyrazinamide analogs 5a–h have been successfully synthesized by the Yamaguchi
esterification method with yields ranging from 6% to 86%. Among pyrazinamides 5a–h …

Assessing the influencing factors of out-of-pocket costs on tuberculosis in Sichuan Province: a cross-sectional study

L Xia, L Gao, Y Zhong, Y Wu, J He, F Zou, R Jian… - BMC Public Health, 2023 - Springer
Background Although diagnosis and treatment services for tuberculosis (TB) are provided
free of charge in most countries, direct non-medical and indirect costs due to absenteeism …

Synthesis of novel furan-based chalcone derivatives as anti-tuberculosis agents: in vitro, cytotoxicity assessment and in silico

LS Dhivya, KM Kumaradoss - Future Medicinal Chemistry, 2023 - Taylor & Francis
Background: The aim of the study is to identify a novel furan-based chalcone derivative as
potent inhibitor against the H37Rv strain. Materials & methods: The in silico pharmacokinetic …

Systematic evaluation of line probe assays for the diagnosis of tuberculosis and drug-resistant tuberculosis

M Lin, YW Chen, YR Li, LJ Long, LY Qi, TT Cui… - Clinica Chimica …, 2022 - Elsevier
Abstract Background Line probe assays (LPAs) are PCR-based assays used for the rapid
diagnosis of Mycobacterium tuberculosis (MTB) and drug-resistant tuberculosis (DR-TB). But …

Abnormal Tryptophan Metabolism in HIV and Mycobacterium tuberculosis Infection

X Wang, S Mehra, D Kaushal, RS Veazey… - Frontiers in …, 2021 - frontiersin.org
Host metabolism has recently gained more attention for its roles in physiological functions
and pathologic conditions. Of these, metabolic tryptophan disorders generate a pattern of …

Prophylactic Sublingual Immunization with Mycobacterium tuberculosis Subunit Vaccine Incorporating the Natural Killer T Cell Agonist Alpha-Galactosylceramide …

A Khan, S Singh, G Galvan, C Jagannath, KJ Sastry - Vaccines, 2017 - mdpi.com
Infection by Mycobacterium tuberculosis (Mtb) remains a major global concern and the
available Bacillus Calmette-Guerin (BCG) vaccine is poorly efficacious in adults. Therefore …